PharmAla Biotech

25/09/2025

PharmAla is pleased to announce that it has signed an agreement with Veridion Group to act as its distribution partner in New Zealand.

New Zealand’s Medsafe agency recently approved the first authorized psychiatrist allowed to treat patients with Psilocybin, and several applications are underway for authorization to implement M**A-Assisted Therapy for PTSD.

08/09/2025

PharmAla is happy to announce that it has completed import operations and release to the United States. PharmAla announced contracting of this new distribution site on March 24, 2025.

Press Release: https://pharmala.ca/media/2025/09/pharmala-completes-import-of-laneo-mdma-for-u-s-distribution

We are a Canadian biotechnology company dedicated to the domestic research, development and manufacturing of clinical-grade M**A and novel MDXX compounds in service to the scientific research community.

08/09/2025

Will Avery, PharmAla Biotech CFO, highlights key financial milestones: FY24 revenue up 95% to $1 M+; resumed SAP shipments in Canada & the U.S.; expanded clinical trial deliveries via a new U.S. distributor; and raised $1.5 M+ through Q3 ’25.

03/09/2025

PharmAla is pleased to announce that it has incorporated PharmAla Biotech Australia Pty Ltd. , a wholly-owned Australian subsidiary, for the purposes of conducting research and development activities in Australia.

Press release: https://pharmala.ca/media/2025/09/pharmala-incorporates-australian-entity-for-clinical-research

We are a Canadian biotechnology company dedicated to the domestic research, development and manufacturing of clinical-grade M**A and novel MDXX compounds in service to the scientific research community.

10/06/2025

See you in Denver! We are proud to be speaking at , the largest psychedelic conference of its kind! Join MAPS from June 16-20 for Psychedelic Science 2025 at the Colorado Convention Center in Denver, Colorado. Featuring educational stages, an immersive expo hall, workshops, and community— you do not want to miss the integration!

30/05/2025

PharmAla has been made aware of individuals falsely selling illegal products using our brand name. PharmAla only sells its products via Health Canada authorization and for legitimate medical need. Please see our release:

We are a Canadian biotechnology company dedicated to the domestic research, development and manufacturing of clinical-grade M**A and novel MDXX compounds in service to the scientific research community.

26/05/2025

We don’t just need new drugs — we need new policies.
PharmAla CEO Nick Kadysh explains why regulators must adapt to AI-powered drug discovery if we want to see breakthroughs in mental health, neurology, and rare disease.

https://canadahealthwatch.ca/2025/05/23/ai-is-rewiring-drug-discovery-regulators-must-keep-up

The future of drug discovery will be driven by code.

15/05/2025

PharmAla is thrilled to formally announce the launch of the Phenesafe AI platform, an AI technology stack specifically designed to derive novel substituted phenethylamine molecules for patent and subsequent development.

Press Release: https://pharmala.ca/media/2025/05/pharmala-biotech-launches-phenesafe-ai-drug-discovery-platform-for-novel-phenethylamines

01/04/2025

🚨 PsyCan is calling on leaders to enhance access to psychedelic medicine for veterans and those battling mental health issues.

Let’s push for change and support innovative therapies! Read more about this urgent call to action here: https://psychedelicscanada.org/media/2025/03/federalelection2025release

TORONTO, ON | April 1, 2025 — PsyCan, the national trade association representing Canada’s legally operating psychedelic medicine and therapy companies, is calling on the Carney and Poilievre campaigns to commit to enhancing research, affordability, and access to psychedelic medicine for veteran...

24/03/2025

PharmAla is pleased to announce that it has contracted with a third party logistics company specializing in pharmaceutical products to act as its US clinical trial distribution partner.

https://pharmala.ca/media/2025/03/pharmala-contracts-with-partner-to-act-as-us-distributor

We are a Canadian biotechnology company dedicated to the domestic research, development and manufacturing of clinical-grade M**A and novel MDXX compounds in service to the scientific research community.

10/03/2025

PharmAla is excited to announce that it has signed a distribution agreement with Duchefa Farma of Haarlem, Netherlands, to act as exclusive distribution agent for its LaNeo M**A in the Netherlands market.

We are a Canadian biotechnology company dedicated to the domestic research, development and manufacturing of clinical-grade M**A and novel MDXX compounds in service to the scientific research community.